®()

Ozempic®(Semaglutide)

Prescription Only

Ozempic (semaglutide) is a once-weekly injection that helps improve blood sugar levels in adults with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular...

Dosage & Administration

Administration

Learn more.

Subcutaneous. Learn more.

Dosing

Learn more.

0.25 mg SC injection q/week for 4 weeks. After 4 weeks, increase to 0.5 mg SC q/week. • If more control needed after 4 weeks on 0.5 mg, increase to 1 mg SC q/week • If further control needed after 4 weeks on 1 mg, increase to 2 mg SC q/week (max dose). . Learn more.

Latin Shorthand

Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

Learn more.

$25. Learn more.

Annual Cap

Learn more.

$150 for 1 month supply; $300 for 2 month supply; $450 for 3 month supply. Learn more.

Assistance Expiration

Learn more.

24 months. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

Learn more.

The most common adverse reactions, reported in ≥5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation.. Learn more.

Mechanism of Actions (MoA)

Learn more.

GLP-1 Receptor Agonists. Learn more.

Special Populations

What is the risk of using OZEMPIC® during pregnancy?

Limited data exist on the use of semaglutide in pregnant women, making it challenging to determine the potential drug-associated risk for adverse developmental outcomes. Poorly controlled diabetes during pregnancy poses risks for both the mother and fetus. OZEMPIC® should be used during pregnancy only if the potential benefits outweigh the potential risks.

What are the potential risks to the fetus from exposure to semaglutide during pregnancy?

Based on animal studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. In pregnant rats, exposure to semaglutide during organogenesis led to embryofetal mortality, structural abnormalities, and growth alterations. Similar findings were observed in rabbits and cynomolgus monkeys.

What is the estimated background risk of birth defects and miscarriage in pregnant women?

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

What are the disease-associated risks for pregnant women with poorly controlled diabetes?

Poorly controlled diabetes during pregnancy increases the risk of hypoglycemia, hyperglycemia, diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. It also increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.

What do the animal data reveal about the effects of semaglutide exposure during pregnancy?

Animal data indicate that exposure to semaglutide during pregnancy in rats, rabbits, and cynomolgus monkeys can result in embryofetal mortality, structural abnormalities, and alterations in growth. These effects were observed at various dose levels and exposures in different animal species.

What is known about semaglutide exposure during lactation?

There is no information available regarding the presence of semaglutide in human milk or its effects on breastfed infants or milk production. Semaglutide was detected in the milk of lactating rats, but the clinical relevance of these findings is not clear.

Should OZEMPIC® be discontinued in women planning a pregnancy?

OZEMPIC® should be discontinued in women at least 2 months before planning a pregnancy due to the long washout period required for semaglutide.

Is OZEMPIC® safe for pediatric use?

Safety and efficacy of OZEMPIC® have not been established in pediatric patients (younger than 18 years).

Is OZEMPIC® safe for geriatric use?

No overall differences in safety or efficacy have been detected between older and younger patients in clinical trials. However, caution should be exercised in geriatric patients.

Is OZEMPIC® safe for patients with renal impairment?

No dose adjustment of OZEMPIC® is recommended for patients with renal impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with renal impairment, including end-stage renal disease.

Is OZEMPIC® safe for patients with hepatic impairment?

No dose adjustment of OZEMPIC® is recommended for patients with hepatic impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with varying degrees of hepatic impairment.

®()	Ozempic®(Semaglutide)

Prescription Only	Prescription Only Ozempic (semaglutide) is a once-weekly injection that helps improve blood sugar levels in adults with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular...
Dosage & Administration	Dosage & Administration comparison data
Administration
Learn more.	Subcutaneous. Learn more.
Dosing
Learn more.	0.25 mg SC injection q/week for 4 weeks. After 4 weeks, increase to 0.5 mg SC q/week. • If more control needed after 4 weeks on 0.5 mg, increase to 1 mg SC q/week • If further control needed after 4 weeks on 1 mg, increase to 2 mg SC q/week (max dose). . Learn more.
Latin Shorthand
Learn more.	0.25 mg SC injection q/week for 4 weeks. After 4 weeks, increase to 0.5 mg SC q/week. • If more control needed after 4 weeks on 0.5 mg, increase to 1 mg SC q/week • If further control needed after 4 weeks on 1 mg, increase to 2 mg SC q/week (max dose). . Learn more.
Financial Assistance	Financial Assistance comparison data
Out-Of-Pocket Costs With Copay Card
Learn more.	$25. Learn more.
Annual Cap
Learn more.	$150 for 1 month supply; $300 for 2 month supply; $450 for 3 month supply. Learn more.
Assistance Expiration
Learn more.	24 months. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Physician Advisory	Physician Advisory comparison data
Adverse Reactions
Learn more.	The most common adverse reactions, reported in ≥5% of patients treated with OZEMPIC® are: nausea, vomiting, diarrhea, abdominal pain and constipation.. Learn more.
Mechanism of Actions (MoA)
Learn more.	GLP-1 Receptor Agonists. Learn more.
Special Populations
	What is the risk of using OZEMPIC® during pregnancy? Limited data exist on the use of semaglutide in pregnant women, making it challenging to determine the potential drug-associated risk for adverse developmental outcomes. Poorly controlled diabetes during pregnancy poses risks for both the mother and fetus. OZEMPIC® should be used during pregnancy only if the potential benefits outweigh the potential risks. What are the potential risks to the fetus from exposure to semaglutide during pregnancy? Based on animal studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. In pregnant rats, exposure to semaglutide during organogenesis led to embryofetal mortality, structural abnormalities, and growth alterations. Similar findings were observed in rabbits and cynomolgus monkeys. What is the estimated background risk of birth defects and miscarriage in pregnant women? In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. What are the disease-associated risks for pregnant women with poorly controlled diabetes? Poorly controlled diabetes during pregnancy increases the risk of hypoglycemia, hyperglycemia, diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. It also increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity. What do the animal data reveal about the effects of semaglutide exposure during pregnancy? Animal data indicate that exposure to semaglutide during pregnancy in rats, rabbits, and cynomolgus monkeys can result in embryofetal mortality, structural abnormalities, and alterations in growth. These effects were observed at various dose levels and exposures in different animal species. What is known about semaglutide exposure during lactation? There is no information available regarding the presence of semaglutide in human milk or its effects on breastfed infants or milk production. Semaglutide was detected in the milk of lactating rats, but the clinical relevance of these findings is not clear. Should OZEMPIC® be discontinued in women planning a pregnancy? OZEMPIC® should be discontinued in women at least 2 months before planning a pregnancy due to the long washout period required for semaglutide. Is OZEMPIC® safe for pediatric use? Safety and efficacy of OZEMPIC® have not been established in pediatric patients (younger than 18 years). Is OZEMPIC® safe for geriatric use? No overall differences in safety or efficacy have been detected between older and younger patients in clinical trials. However, caution should be exercised in geriatric patients. Is OZEMPIC® safe for patients with renal impairment? No dose adjustment of OZEMPIC® is recommended for patients with renal impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with renal impairment, including end-stage renal disease. Is OZEMPIC® safe for patients with hepatic impairment? No dose adjustment of OZEMPIC® is recommended for patients with hepatic impairment. Semaglutide pharmacokinetics have not shown clinically relevant changes in subjects with varying degrees of hepatic impairment.

® Alternatives